Slide 1: Interim Results for the 6 Months Period Ending 30th June 2021
TM pre|CISION pre|CISION TM Interim Results for the 6 Months Period Ending 30th June 2021 September 30th, 2021 © Avacta Group plc 1
Slide 2: Disclaimer: Important Notice
Disclaimer: Important Notice TM pre|CISION No representation or warranty, expressed or implied, is made or given by or on behalf of Avacta Group plc (the “Company” and, together with its subsidiaries and subsidiary undertakings, the “Group”) or any of its directors or any other person as to the accu
Slide 3: Introduction
TM pre|CISION Introduction © Avacta Group plc 3
Slide 4: Today's Presentation Team
Today’s Presentation Team TM pre|CISION Dr Alastair Smith, CEO • Over 15 years experience as a life sciences public company CEO. • Science background with 13 years in academia – established a leading UK biophysics group. • Founded Avacta in 2006. • World class scientific and technical knowledge with
Slide 5: Our Mission
Our Mission pre|CISION TM Shaping the future of medicine with powerful therapeutic and diagnostic platforms © Avacta Group plc 5
Slide 6: Group Overview
Group Overview TM pre|CISION Diagnostics Division • In-vitro diagnostics company based in Wetherby, UK • R&D Centre and plc Headquarters LSE: AVCT • 49 (inc 22 PhDs) scientists/technicians • First Affimer IVD launched: AffiDX® SARS-CoV-2 antigen ````` lateral flow test Therapeutics Division • In-hou
Slide 7: Interim Results for the Period Ended June 2021
TM pre|CISION Interim Results for the Period Ended 30 June 2021 th © Avacta Group plc 7
Slide 8: Interim Results: Income Statement
Interim Results for the Period Ending 30th June 2021 : Income Statement TM pre|CISION 6 months ended 6 months ended 12 months ended 30 June 2021 30 June 2020 31 December 2020 (£m) (£m) (£m) Revenue 2.32 1.81 3.64 Gross profit 1.51 1.22 2.18 Gross margin 65% 68% 60% R&D & Amortisation costs (6.70) (4
Slide 9: Interim Results: Cash Flow and Balance Sheet
Interim Results for the Period Ending 30th June 2021 : Cash Flow and Balance Sheet TM pre|CISION 30th June 2021 30th June 2020 31st Dec 2020 (£m) (£m) Operating activities (8.82) (5.48) (14.07) Working capital (1.38) 1.08 0.72 Tax and interest (0.05) (0.01) 2.70 Investment (exc. deposits) (0.80) (1.
Slide 10: Innovative Cancer Therapies
TM pre|CISION Innovative Cancer Therapies © Avacta Group plc 10
Slide 11: preCISION Tumour Targeted Activation of Cancer Therapies
pre|CISIONTM Tumour Targeted Activation of Cancer Therapies TM pre|CISION What is pre|CISIONTM? “FAP High” tumours • pre|CISION is a highly specific substrate for fibroblast activation protein-a (FAPa), an extracellular enzyme that is highly upregulated in most solid tumours. • pre|CISION prevents c
Slide 12: The preCISION Platform in Detail
The pre|CISIONTM Platform in Detail TM pre|CISION Reducing the side-effects of chemotherapy by tumour-specific activation AVA6000 Active Doxorubicin Tumour Microenvironment Cancer cells Naïve T cells 2 FAPa Macrophage B cells Fibroblast FAPa +ve fibroblasts and cancer cells © Avacta Group plc 12
Slide 13: The Benefit to Patients
The Benefit to Patients TM pre|CISION Reducing the side-effects of chemotherapy by tumour-specific activation Standard Chemo Systemic Dosing pre|CISION Prodrug Systemic Dosing All organs equally exposed to chemotherapy- The prodrug is expected to be distributed around the body with leads to poor tol
Slide 14: preCISION Pro-drugs: AVA6000 Pro-doxorubicin
pre|CISIONTM Pro-drugs AVA6000 Pro-doxorubicin TM pre|CISION AVA6000 addresses the safety issues of a $1bn generic chemotherapy Background Targeting of Drug to Tumour Spares Heart Tissue Doxorubicin has been a standard of care treatment for 18x more active chemotherapy in the tumour compared with th
Slide 15: AVA6000 Phase I Design and Timeline
AVA6000 Phase I Design and Timeline pre|CISION TM 2020 2021 2022 2023 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 CTA CTA First Pt pK Data First Pt Dosed Last Pt Out Subm. Approve Dosed Cohort 1 (Exp) (Exp) d Phase I Safety & pK Study Approvals & Study Set Up Phase Ia - Dose Escalation Update Phase 1a • Up to
Slide 16: The Wider preCISION Pro-drug Opportunity
The Wider pre|CISIONTM Pro-drug Opportunity TM pre|CISION pre|CISIONTM can be widely applied to a range of other chemotherapies in a market worth $56.5B with CAGR of 11.50% driven by increased cancer detection rates Example: Velcade Ideal for pre|CISIONTM tumour activation to create • Bortezomib (Ve
Slide 17: Partnered Programmes Update
Partnered Programmes Update TM pre|CISION Life Sciences • (2018) multi-target agreement to develop Affimer® • (2021) a license for Avacta’s pre|CISION technology for therapeutics in several disease areas. the development of tumour-activated radiopharmaceuticals. • (2020) partnership expanded to incl
Slide 18: Scientific Advisory Board
Scientific Advisory Board pre|CISION TM Professor James Spicer MB., BA., PhD., FRCP is Professor of Experimental Cancer Medicine in the School of Cancer & Pharmaceutical Studies at King’s College London, and Consultant in Medical Oncology at Guy’s & St. Thomas’ Hospitals. He has a PhD in cancer biol
Slide 19: Powerful Diagnostics
TM pre|CISION Powerful Diagnostics © Avacta Group plc 19
Slide 20: AffiDX SARS-CoV-2 Antigen Rapid Test
AffiDX® SARS-CoV-2 Antigen Rapid Test TM pre|CISION A 20 minutes rapid antigen test using anterior nasal sampling INTENDED USE: The Avacta® AffiDX® SARS-CoV-2 antigen lateral flow test is a qualitative in vitro diagnostic (IVD) test to detect SARS-CoV-2 antigen in human anterior nasal swab samples.
Slide 21: AffiDX SARS-CoV-2 Antigen Rapid Test
AffiDX® SARS-CoV-2 Antigen Rapid Test TM pre|CISION https://avacta.com/diagnostics/products/validation-of-affidx-sars-cov-2-antigen-lft-with-variants-of-concern/ © Avacta Group plc 21
Slide 22: AffiDX SARS-CoV-2 Antigen Rapid Test Clinical Performance
AffiDX® SARS-CoV-2 Antigen Rapid Test Clinical Performance TM pre|CISION Clinical Sensitivity (Ct<31) 98.0%; Clinical Specificity 99% PCR1 Avacta® AffiDX® Clinical Sensitivity by Ct Range1 Number of Samples Result Tested in Ct Range Cumulative % Cumulative (Ct Range) Positive Negative 95% CI Ct Rang
Slide 23: AffiDX SARS-CoV-2 Antigen Rapid Test Commercial Roll-out
AffiDX® SARS-CoV-2 Antigen Rapid Test Commercial Roll-out TM pre|CISION Growing commercial traction for AffiDX professional-use antigen test and significant progress towards self-test approval • Current manufacturing capacity at GAD now c.1 million tests per month. • Manufacturing process has been t
Slide 24: Summary
Summary TM pre|CISION First ever Affimer® IVD product brought to market and first-in-human phase I study of first preCISION pro-drug initiated • Diagnostics • There will be an ongoing global need for sensitive and reliable COVID-19 testing for many years. • AffiDX SARS-CoV-2 antigen flow test with m
Slide 25: Broker and Nominated Adviser
TM pre|CISION Broker and Nominated Adviser Stifel Nicolaus Europe Limited Nicholas Moore / Nick Adams / Fred Walsh / Ben Maddison nicholas.moore@stifel.com ben.maddison@stifel.com nick.adams@stifel.com fred.walsh@stifel.com www.stifel.com Tel: +44 (0) 207 710 7600 FTI Consulting (Financial Media and